ClinicalTrials.Veeva

Menu

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

G

Grupo Español Multidisciplinar de Melanoma

Status

Completed

Conditions

Stage IV Skin Melanoma

Study type

Observational

Funder types

Other

Identifiers

NCT01960634
GEM-1304 (Other Identifier)

Details and patient eligibility

About

This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples.

Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard medical practice.

The treatment is not the aim of the study. Patients can be treated either with specific or no-specific drug.

Enrollment

58 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Confirmed diagnosis of melanoma and BRAFV600
  • Signed Informed Consent Form
  • Unresectable phase III or phase IV melanoma
  • The patients should be starting a treatment for melanoma (either first line or subsequent lines)

Trial contacts and locations

13

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems